Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

IMPORTANCE: Peptide receptor radionuclide therapy (PRRT) is approved in the US for treatment of gastroenteropancreatic neuroendocrine tumors (NETs), but data on PRRT outcomes within US populations remain scarce. OBJECTIVE: To analyze the first 2 years of PRRT implementation at a US-based NET referra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kipnis, Sarit T., Hung, Matthew, Kumar, Shria, Heckert, Jason M., Lee, Hwan, Bennett, Bonita, Soulen, Michael C., Pryma, Daniel A., Mankoff, David A., Metz, David C., Eads, Jennifer R., Katona, Bryson W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988364/
https://www.ncbi.nlm.nih.gov/pubmed/33755166
http://dx.doi.org/10.1001/jamanetworkopen.2021.2274

Ejemplares similares

Ejemplares similares